SCHEMBL29514101

SCHEMBL29514101

COc1nc(Cl)c(C=O)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
MPI P34949 1/20 0.41
ERN1 O75460 7/20 0.37
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 3/20 0.34
HPGD P15428 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TRIM24 O15164 1/20 0.32
TYR P14679 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25347030 1.00 PRKDC (0.44) PRKDCCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL31541661 0.79 PRKDC (0.44) PRKDCCYP3A4ALDH1A1KDM4EMAPT
SCHEMBL21582002 0.77 CYP1A2 (0.51) PRKDCCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL25343459 0.76 TDP1 (0.44) CYP1A2CYP3A4ALDH1A1KMT2AMAPT
SCHEMBL30519502 0.76 TDP1 (0.44) CYP1A2CYP3A4ALDH1A1KMT2AMAPT
SCHEMBL20539389 0.75 TDP1 (0.41) PRKDCCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL29580781 0.75 TDP1 (0.41) PRKDCCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20719582 0.74 ALDH1A1 (0.42) PRKDCCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30448383 0.74 ALDH1A1 (0.42) PRKDCCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL16896834 0.73 CYP1A2 (0.56) PRKDCCYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076973-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed